Insulin production
Type 1 diabetes
An autoimmune condition in which the body stops producing insulin. It can develop at any age and requires insulin treatment.
Global Health Challenges/Diabetes
Diabetes Global ChallengeDiabetes
Global Challenge
Ecosystem
Explore the global diabetes landscape through population data, diagnostic evidence, patient pathways and treatment coverage. Connect research, clinical expertise and innovation to support better understanding and care.
Diabetes research and careA global perspective.
A focus on people.
Explore the patient journey ↗Conceptual editorial imageA focus on people.
589million
adults aged 20–79 living with diabetes
IDF estimate · 2024 ↗Population evidence → diagnosis → care → access
183companiesin the research database↗733trial recordsin the research database↗50investorsin the research database↗102clinicsin the research database↗
Research database coverage · supplied October 2026 snapshot · trial records include different study types and statuses
Understanding diabetes
Different types.
Different care needs.
Understanding the different forms of diabetes is essential for interpreting research, identifying care needs and developing appropriate prevention and management strategies.
Insulin action
Type 2 diabetes
The body does not use insulin effectively and may gradually produce too little. Prevention, earlier detection and continued care all matter.
The wider picture
Gestational diabetes
Elevated blood glucose during pregnancy.
Intermediate glucose states
Impaired glucose tolerance and fasting glycaemia also matter in the wider landscape.
The interactive views focus on type 1, type 2 and combined diabetes evidence.
Read the WHO overview ↗Explore the evidence
Five perspectives.
One connected challenge.
Choose a question to explore the data behind it.
The global picture
Global diabetes incidence and prevalence
Explore incidence and prevalence, with reported and estimated layers kept distinct. Filter by diabetes type and year to see both the patterns and the gaps in the evidence.
The people behind the data
Diabetes patient profiles
Compare age and sex patterns in selected countries, then explore published complication profiles. The two panels describe different populations and sources.
The diagnostic perspective
Diabetes diagnostics
and test accuracy
Explore published sensitivity, specificity and uncertainty across 11 test and risk-assessment methods. Compare the evidence behind a result, not just the headline percentage.
The patient journey
Diabetes patient journey
Follow the steps from onset and testing to treatment and control. Switch between type 1 and type 2 pathways and compare the available care-cascade evidence.
The access question
Diabetes burden and
treatment coverage
Compare prevalence with the share of people with diabetes taking glucose-lowering medication. Explore where high burden meets lower coverage, and which populations sit behind each point.
From understanding to action
Research, innovation
and collaboration
Explore opportunities to connect research, clinical practice and technology, with a focus on earlier diagnosis, continuity of care and access to treatment.
Health-system perspective
Understanding treatment gaps
Compare diabetes prevalence and medication coverage to identify differences in treatment access across countries.
Explore access40/ 195
high burden / lower coverage
Explore diagnostic evidence
Compare test performance together with uncertainty, thresholds and source methods.
Explore diagnostics ↗Collaboration opportunities
Work with GHC on diabetes research, analytics and initiatives connecting clinical insight, data and technology.
Partner with GHC ↗Inside the research database
The diabetes ecosystem, in context
Explore a research landscape spanning therapeutics, digital health, cell and gene therapies, glucose monitoring and insulin delivery.
9 company segments52 research and ecosystem hubs
Explore the interactive evidence ↗Leading company segments
Database recordsTherapeutics
61
Digital Health
24
Cell & Gene Therapy
22
Insulin Delivery
21
The five interactive visualisations cover selected population, diagnostic and care datasets. Their coverage differs from the wider database. Counts describe supplied research records, not the complete global market.
The research library
Diabetes research materials
Explore Diabetes and Metabolic Global Overview 2026 through the one-pager, teaser and full report.
Coming soonDiabetes
Diabetes Global Challenge
Diabetes
Intelligence Platform
A planned environment for exploring diabetes evidence, diagnostics, patient pathways and access in one place.
- Population evidence, with source and year context
- Diagnostic performance and research methods
- Type 1 and type 2 care pathways
- Comparisons of burden and treatment coverage
Diabetes IntelligenceOverviewPopulationDiagnosticsCare
Region: GlobalType: AllEvidence overviewConcept preview
Companies183Research database
Trial Records733Research database
Investors50Research database
Clinics102Research database
Global prevalence landscape2024
LowerHigher
Adults aged 20–79 · IDF estimated prevalenceBurden & treatment coverage195 countries
40 / 195high burden / lower coverage
Selected highest map estimatesPrevalence
Pakistan31.4%2024
Marshall Islands25.7%2024
Kuwait25.6%2024
Concept preview · supplied research datasets · source periods differ between views
Connect evidence with expertise
Join the Diabetes
Global Challenge Ecosystem
Connect with Global Health Challenges to explore research, analytical and partnership opportunities in diabetes.
Sources, coverage and interpretation +
Global context
The 589 million estimate refers to adults aged 20–79 in 2024, including diagnosed and undiagnosed diabetes. It is not the number of diagnosed cases alone.
IDF Diabetes Atlas, 11th edition ↗WHO: Diabetes questions and answers ↗Interactive evidence
The five supplied datasets retain their source records, periods and methodological notes. The map includes 209 territories for prevalence but only 10 countries with reported incidence records. Different chart selections may use different populations and years.
These materials support research and exploration; they do not provide individual diagnosis or treatment advice.